Neurodegeneration: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
'''Neurodegeneration''' describes the loss of structure or function to nervous tissue<ref>Merriam-Webster. (n.d.). Medical Dictionary. | '''Neurodegeneration''' describes the loss of structure or function to nervous tissue<ref>Merriam-Webster. (n.d.). Medical Dictionary. Available: http://www.merriam-webster.com/medlineplus/neurodegeneration. Last accessed 09/11/2014.</ref>. Neurodegenerative diseases include [https://teaching.ncl.ac.uk/bms/wiki/index.php/Alzheimers_Disease Alzheimer’s], [https://teaching.ncl.ac.uk/bms/wiki/index.php/ALS ALS], [https://teaching.ncl.ac.uk/bms/wiki/index.php/Huntingtons_Disease Huntington’s] and [https://teaching.ncl.ac.uk/bms/wiki/index.php/Parkinsons_Disease Parkinson’s]<ref>Bredeson, D. (2006). Cell death in the nervous system. Nature, 796-802.</ref>. | ||
<span style="line-height: 1.5em;">Most of the physiological mechanisms whereby neurodegenerative diseases develop and progress share the common feature where [https://teaching.ncl.ac.uk/bms/wiki/index.php/Protein_aggregation proteins aggregate] – that is, the accumulation of misfolded proteins which clump together either intra or extracellularly<ref>Aguzzi, A., &amp; O'Connor, T. (2010). Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature, 237-248.</ref>. This feature suggests a commonality of the pathological processes of neurodegenerative diseases; this might allow for neuroprotective medicine to be developed to counter protein accumulation<ref>Nieoullon, A. (2011). Neurodegenerative diseases and neuroprotection: current views and prospects. Journal of Applied Biomedicine, 173-183.</ref>.</span> | <span style="line-height: 1.5em;">Most of the physiological mechanisms whereby neurodegenerative diseases develop and progress share the common feature where [https://teaching.ncl.ac.uk/bms/wiki/index.php/Protein_aggregation proteins aggregate] – that is, the accumulation of misfolded proteins which clump together either intra or extracellularly<ref>Aguzzi, A., &amp;amp;amp; O'Connor, T. (2010). Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature, 237-248.</ref>. This feature suggests a commonality of the pathological processes of neurodegenerative diseases; this might allow for neuroprotective medicine to be developed to counter protein accumulation<ref>Nieoullon, A. (2011). Neurodegenerative diseases and neuroprotection: current views and prospects. Journal of Applied Biomedicine, 173-183.</ref>.</span> | ||
<br> | <br> | ||
<span style="line-height: 1.5em;"><references /></span><br> | <span style="line-height: 1.5em;"><references /></span><br> | ||
Revision as of 18:18, 9 November 2014
Neurodegeneration describes the loss of structure or function to nervous tissue[1]. Neurodegenerative diseases include Alzheimer’s, ALS, Huntington’s and Parkinson’s[2].
Most of the physiological mechanisms whereby neurodegenerative diseases develop and progress share the common feature where proteins aggregate – that is, the accumulation of misfolded proteins which clump together either intra or extracellularly[3]. This feature suggests a commonality of the pathological processes of neurodegenerative diseases; this might allow for neuroprotective medicine to be developed to counter protein accumulation[4].
- ↑ Merriam-Webster. (n.d.). Medical Dictionary. Available: http://www.merriam-webster.com/medlineplus/neurodegeneration. Last accessed 09/11/2014.
- ↑ Bredeson, D. (2006). Cell death in the nervous system. Nature, 796-802.
- ↑ Aguzzi, A., &amp;amp; O'Connor, T. (2010). Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nature, 237-248.
- ↑ Nieoullon, A. (2011). Neurodegenerative diseases and neuroprotection: current views and prospects. Journal of Applied Biomedicine, 173-183.